

USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office				Attorney Docket No. 66015(45120)		Serial No. 10/587,775		
INFORMATION DISCLOSURE STATEMENT				Applicant(s): Elmen et al				
				Filing Date: July 28, 2006		Group: 1623		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
	A4	5,898,031	4/27/1999	Crooke				
	A2	6,107,094	8/22/2000	Crooke				
	A3	6,506,559	1/14/2003	Fire et al.				
	A4	7,056,704	6/6/2006	Tuschl et al.				
	A5	7,078,196	7/18/2006	Tuschl et al.				
	A6	7,432,250	10/7/2008	Crooke				
	A7	2004/0053875	3/18/2004	Kreutzer et al.				
	A8	2007/0191294	8/16/2007	Elmen et al.				
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
	B1	EP0928290	3/30/2005	EP				
	B2	EP1214945	6/8/2005	EP			US04/0053875	
	B3	EP1407044	9/19/2007	EP				
	B4	EP1550719	12/24/2008	EP			US04/0053875	
	B5	WO2004/083430	9/30/2004	PCT				
	B6	WO2004/099387	11/18/2004	PCT				
	B7	WO2006/050734	5/18/2006	PCT				
	B8	WO2007/056153	5/18/2007	PCT				
	B9	WO2007/085485	8/2/2007	PCT				
	B10	WO2007/107162	9/27/2007	PCT				
	B11	WO2008/049078	4/24/2008	PCT				

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
	C1	Birmingham et al., "3' UTR seed matches, but not overall identity, are associated with RNAi off-targets," Nature Methods (2006), 3(3):199-204
	C2	Bramsen et al., "Improved silencing properties using small internally segmented interfering RNAs," Nucleic Acids Research (2007), 35(17):5886-5897
	C3	Elmen et al., "Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality," Nucleic Acids Research (2005), 33(1):439-447
	C4	Frieden et al., "Expanding the design horizon on antisense oligonucleotides with alpha-L-LNA," Nucleic Acids Research (2003), 31(21):6365-6372
	C5	Jackson et al., "Expression profiling reveals off-target gene regulation by RNAi," Nature Biotechnology (2003), 21(6):635-638
	C6	Jackson et al., "Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity," RNA (2006), 12:1179-1187
	C7	Kumar et al., "The First Analogues of LNA (Locked Nucleic Acids): Phosphorothioate-LNA and 2'-thio-LNA," Bioorganic & Medicinal Chemistry Letters (1998), 8:2219-2222
	C8	Leuschner et al., "Cleavage of the siRNA passenger strand during RISC assembly in human cells," EMBO Reports (2006), 7(3):314-320
	C9	Maiti et al., "QIP, a putative exonuclease, interacts with the Neurospora Argonaute protein and facilitates conversion of duplex siRNA into single strands," Genes & Development (2007), 21:590-600
	C10	Matranga et al., "Passenger-Strand Cleavage Facilitates Assembly of siRNA into Ago2-Containing RNAi Enzyme Complexes," Cell (2005), 123:607-620
	C11	Petersen et al., "LNA: a versatile tool for therapeutics and genomics," Trends in Biotechnology (2003), 21(2):74-81
	C12	Schwarz et al., "Asymmetry in the Assembly of the RNAi Enzyme Complex," Cell (2003), 115:199-208
	C13	Soutschek et al., "Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs," Nature (2004) 432:173-178
	C14	Thompson, J.D., "Applications of antisense and siRNAs during preclinical drug development," Drug Discovery Today (2002), 7(17):912-917
EXAMINER /Jon Angell/		DATE CONSIDERED 02/27/2011
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</small>		
<small>**Copies of references not provided at the time of this submission.</small>		